Navigation Links
BIDMC scientists awarded grants from Michael J. Fox Foundation for Parkinson's research
Date:11/18/2009

BOSTON -- Beth Israel Deaconess Medical Center (BIDMC) neurologists Alvaro Pascual-Leone, MD, PhD, and Daniel Tarsy, MD, have been awarded grants totaling more than $1.5 million from the Michael J. Fox Foundation for Parkinson's Research (MJFF) to conduct investigations aimed at improving the quality of life for patients with Parkinson's disease.

A chronic, degenerative disorder of the nervous system that affects one in 100 individuals over age 60, Parkinson's disease results from diminished levels of dopamine, the brain's chemical messenger responsible for transmitting the signals that enable us to coordinate movements. Although Parkinson's disease typically results in tremor, rigidity and other motor symptoms, a number of non-motor symptoms, including depression, cognitive impairment, and sleep problems can also affect patients with Parkinson's disease and, in many cases, can be even more disabling than the motor symptoms.

Pascual-Leone, Director of BIDMC's Berenson-Allen Center for Noninvasive Brain Stimulation, will oversee a three-year $1.498 million grant to investigate the use of repetitive transcranial magnetic stimulation (rTMS) therapy to control symptoms of Parkinson's disease. As part of the study, 160 patients will be enrolled in clinical trials at BIDMC and at three other North American centers including the University of Florida in Gainesville, the University of California in Los Angeles, and the Toronto (Canada) Western Research Institute-University of Toronto.

"Depression is very common among patients with Parkinson's disease and evidence suggests that it is not merely a response to chronic illness or motor impairments but, in fact, results from factors related to the degenerative brain process itself," notes Pascual-Leone, whose pioneering work has demonstrated that TMS therapy in which a mild electric current is delivered through a magnetic coil placed over a patient's scalp to help adjust brain signals that have gone awry can successfully treat depression in patients who have not responded to other therapies.

"Often patients with Parkinson's disease have significant motor problems despite treatment with medications," explains Pascual-Leone. "In our study, noninvasive brain stimulation will target one or both of two brain regions involved in motor or mood symptoms. We predict that rTMS will improve motor symptoms, depression, or both, depending on which brain regions are stimulated, and consequently, will become a valuable adjunct to medications."

In the second MJFF-funded project, Daniel Tarsy, MD, Director of BIDMC's Parkinson's Disease Center, will lead a study comparing two types of speech and voice therapy to determine which is more effective in treating the decreased voice volume experienced by many Parkinson's patients.

"Impaired speech can cause patients to suffer distress, social embarrassment and social isolation," explains Tarsy. "Musical therapy is currently being used for rehabilitation from other types of neurological conditions, such as language impairment following stroke. If singing therapy can also improve voice and speech disorders resulting from Parkinson's disease, this would represent an important alternative to existing speech therapy techniques."


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. BIDMC Chairman of Neurology Clifford B. Saper, M.D., Ph.D., elected to Institute of Medicine
2. Low-Carb Diet Referenced in BIDMC Study Not Related to Atkins
3. BIDMC scientists receive creativity awards from Prostate Cancer Foundation
4. Biotech company cofounded by BIDMC scientists targets natural killer T-cells
5. Healthcare Data Services (HDS) Announces Contract with Beth Israel Deaconess Physician Organization (BIDPO) and Beth Israel Deaconess Medical Center (BIDMC)
6. BIDMC Dyslexia Research Lab celebrates 25th anniversary
7. Scientists find molecular trigger that helps prevent aging and disease
8. Chinese Scientists Develop Database on the Liver
9. Scientists Grow New Penile Tissue in the Lab
10. Social Network for Translational Scientists Launched
11. Antipsychotic Medications Cause Substantial Weight Gain in Children and Adolescents, According to Scientists at the Feinstein Institute for Medical Research and Zucker Hillside Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held last ... Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred ... Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served APDA ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Stuart ... tattoo technology, the PicoSure. Designed to provide the most effective tattoo removal today, Dr. ... with unmatched results. , Developed by Cynosure, the PicoSure has been approved by the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is ... one drop zone to the next using Colorize's dynamic moving camera. Colorize is perfect ... package includes a 3D slideshow environment with 1 to 5 focus points per scene, ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Health and wellness ... relevant to individuals in the event they are experiencing an illness. Migraines are a ... Americans that are afflicted with migraines would not wish the pain on their worst ...
(Date:2/5/2016)... ... 2016 , ... On June 9-10, Las Vegas will host ... (CME) event presented by the Association for Comprehensive Care in Rare Diseases (ACCORD). ... mission is to provide education, tools, and resources to primary care clinicians that ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Bernstein Liebhard LLP today announced that a securities class ... for the District of Arizona on ... or entities who purchased common shares of Insys Therapeutics Inc. ... 3, 2015 through January 25, 2016 (the "Class Period").  The ... of the Securities Exchange Act of 1934.  ...
(Date:2/4/2016)... , Feb. 4, 2016 Global Immunology ... market to drive long-term market growth Summary ... set of chronic disorders that affect 5–7% of ... terms of their symptoms and key patient demographics, ... of immune pathways and an inappropriate immune response. ...
(Date:2/4/2016)... SPRING, Md. , Feb. 4, 2016 In ... Califf , the FDA,s Deputy Commissioner for Medical Products and ... action plan to reassess the agency,s approach to opioid medications. ... epidemic, while still providing patients in pain access to effective ... The FDA will: , Re-examine the risk-benefit paradigm ...
Breaking Medicine Technology: